| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Cel-Sci Corporation$1.16
-0.06 (-4.92%)
F 19Pipeline Score Richly Valued Biotech · Clinical
Market Cap
12.06 M
EPS
-3.48
P/E Ratio
-
Value Trade
212.01 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
3.77 M
Total Assets
17.71 M
Total Liabilities
10.83 M
Equity
6.87 M
D/E Ratio
12,345
10.94 %
Week
-63.21 %
1 Month
-71.31 %
3 Month
-76.68 %
6 Month
-99.77 %
5 Year
-100 %
All Time
Cash Data
Cash Position
1.89 M
Monthly Burn
1.77 M
Runway
0 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
165.58 K
52 Week Range
0.89 - 13.48
% held by Insiders
7.7 %
% held by Institutions
4.61 %
Enterprise Value
18.68 M
Total Shares
8.49 M
Short %
8.81 %
Float Shares
8.15 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Cel-Sci Corporation
117Total events
2Upcoming
23Tier-1 (high impact)
2013 – 2026Coverage
Upcoming catalysts 2
TBD
T2Other Regulator Milestone
Subscribe to view catalyst details
TBD
T2Trial Initiation
Subscribe to view catalyst details
Event history 2
TBD
▲PublicationMultikineApprovedPresentation
Subscribe to view catalyst details
TBD
◆Trial InitiationMultikineApprovedTrial
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
F19
Pipeline Score $0M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.0x
rNPV / MCap Top 18%
Micro Cap (rank 750 of 913)
Percentile RankCel-Sci Corporation has significant pipeline risk (19/100), with $111M risk-adjusted pipeline value, led by LI in Squamous Cell Carcinoma of the Oral Cavity (Phase 3), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LI Monoclonal antibody | Squamous Cell Carcinoma of the Oral Cavity | Phase 3 | NCT01265849 | 48% | $111M | COMPLETED | 928 | - | - | Dec 4, 2020 | - | Aug 19, 2022 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Multikine | head and neck cancer | Phase 3 | 2026-07-30 | five year overall survival rate multikine: 73%; five year overall survival rate standard of care: 45%; hazard ratio: 0.34; risk of death multikine: 27%; risk of death standard of care: 55% Read More | Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients Read More | |
Multikine | head and neck cancer | Phase 3 | 2026-07-30 | five year overall survival rate multikine: 73%; five year overall survival rate standard of care: 45%; hazard ratio: 0.34; risk of death multikine: 27%; risk of death standard of care: 55% Read More | Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients Read More | |
Multikine | head and neck cancer | Phase 3 | 2026-07-30 | five year overall survival rate multikine: 73%; five year overall survival rate standard of care: 45%; hazard ratio: 0.34; risk of death multikine: 27%; risk of death standard of care: 55% Read More | Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CVM
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CVM Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CVM▲ +7%on this news
Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients
CEL-SCI's Multikine Phase 3 data has been accepted for publication in a leading oncology journal. This study demonstrates an overall survival benefit for patients with head and neck cancer, particularly those from underserved populations. The publication marks a significant milestone for CEL-SCI in showcasing the effectiveness of its treatment.
Read more →CVM▼ -11.6%on this news
CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer
CEL-SCI is set to initiate a Phase 3 confirmatory study for Multikine, aimed at obtaining FDA registration. This study focuses on newly diagnosed patients with head and neck cancer, marking a significant step towards bringing this treatment to market. The initiative reflects CEL-SCI's commitment to addressing critical needs in oncology.
Read more →CVMCEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care
CEL-SCI and Saudi Amarox recently held a strategic agreement signing ceremony at BIO 2026. This event marks a significant step in enhancing cooperation between the U.S. and Saudi Arabia in the field of cancer care. The collaboration aims to leverage resources and expertise to improve cancer treatment options.
Read more →CVM▼ -6.5%on this news
Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI CORPORATION ANNOUNCES PRICING OF OFFERING Vienna, VA
CEL-SCI Corporation announced the pricing of a best-efforts offering of 2,500,000 shares of common stock at $1.00 per share, aiming to raise $2.5 million. The funds will be used for the development of their cancer immunotherapy, Multikine, and for general corporate purposes. The offering is set to close on June 16, 2026, pending customary closing conditions. Important to note, the company has emphasized the presence of risks associated with their forward-looking statements regarding regulatory approvals and the clinical efficacy of their product.
Read more →CVM▼ -15.6%on this news
CEL-SCI Corporation Announces Pricing of Public Offering - May 11, 2026
CEL-SCI Corporation has announced a public offering of 6,000,000 shares priced at $1.20 each, aiming to raise approximately $7.2 million. The funds will be allocated towards the development of their cancer immunotherapy, Multikine, and for general corporate purposes. The offering is set to close on May 13, 2026, pending customary conditions.
Read more →CVM▼ -17.1%on this news· ran to -30% by day 1shared move
Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, Va. 22182 USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI Enters Strategic Agreement with Amarox for the Registra
CEL-SCI Corporation has signed a strategic partnership with Amarox for the registration and commercialization of its immunotherapy Multikine in Saudi Arabia. The agreement includes a 50/50 revenue sharing model and Amarox will act as the local regulatory representative with the Saudi Food and Drug Authority. This partnership aims to expedite Multikine's approval as a treatment for head and neck cancer, addressing significant unmet medical needs in the region, with potential expansion to other Gulf Cooperation Council countries.
Read more →CVM▼ -17.1%on this news· ran to -30% by day 1shared move
Boone Boulevard, Suite 802 Vienna, Va. 22182 USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI Corporation Announces Pricing of Public Offering Vienna
CEL-SCI Corporation announced the pricing of a public offering of 6,000,000 shares of its common stock at $1.20 per share, aiming to raise approximately $7.2 million. The proceeds are designated for the development of Multikine, a cancer immunotherapy, as well as working capital and general corporate purposes. The offering is expected to close on May 13, 2026, pending standard closing conditions. The company has previously received Orphan Drug designation from the FDA for Multikine, which targets tumors in patients diagnosed with squamous cell carcinoma of the head and neck.
Read more →CVM▲ +8.4%on this news
CEL-SCI Reports Fiscal First Quarter 2026 Results
CEL-SCI Corporation reported its fiscal first quarter 2026 results, highlighting key milestones including the upcoming enrollment in a U.S. FDA confirmatory trial for Multikine in head and neck cancer. The company aims to submit data for commercialization in the U.S. and other global markets. Financial results showed a reduced net loss compared to the previous year, despite ongoing expenses.
Read more →CVM▲ +10.2%on this news
CEL-SCI Reports Fiscal 2025 Results
CEL-SCI Corporation reported its fiscal 2025 results, highlighting regulatory advancements for its cancer therapy, Multikine, including a Confirmatory Registration trial approved by the FDA. The trial aims to validate previous Phase 3 study results, showing improved survival rates. The company experienced a decrease in net loss but raised concerns regarding its financial sustainability.
Read more →CVM▲ +15.4%on this news
8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI ANNOUNCES PRICING OF $10 MILLION PUBL
CEL-SCI Corporation announced the pricing of a $10 million public offering, selling 1,111,200 shares of common stock at $9.00 each. The offering is set to close on August 29, 2025, pending customary closing conditions. Proceeds will support the development of Multikine, an investigational cancer immunotherapy, along with general corporate purposes and working capital. The offering follows SEC regulations and will strengthen CEL-SCI's financial position in advancing their clinical efforts.
Read more →CVM▼ -7.6%on this news
8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI ANNOUNCES PRICING OF $5.7 MILLION OFF
CEL-SCI Corporation has announced a $5.7 million offering of 1,500,000 shares of its common stock priced at $3.82 each. The proceeds are designated for the continued development of their cancer immunotherapy, Multikine, along with general corporate purposes. The offering is expected to close on July 14, 2025, subject to customary conditions. The company emphasizes the importance of funding its immunotherapy development amidst potential regulatory challenges.
Read more →CVM▼ -11.7%on this news· ran to -52% by day 1
8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI ANNOUNCES PRICING OF PUBLIC OFFERING
CEL-SCI Corporation has announced the pricing of an underwritten public offering of 2,000,000 shares at $2.50 per share, aiming to raise approximately $5 million. The funds will be used for the ongoing development of Multikine and for general corporate purposes. The offering is expected to close on May 23, 2025, subject to customary conditions. The firm has filed the necessary registration with the SEC and plans to continue advancing its cancer immunotherapy pipeline.
Read more →CVM▼ -6.5%on this news
Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI ANNOUNCES PRICING OF $2.5 MILLION OFFERING Vienna, Virg
CEL-SCI Corporation announced the pricing of a $2.5 million offering of 16 million shares aimed at funding the development of its cancer immunotherapy, Multikine. The offering is expected to close soon, contingent on customary conditions. Multikine has shown promise, receiving FDA Orphan Drug designation for treating head and neck cancer. The company emphasizes the importance of supporting patient immune systems during treatment.
Read more →CVM▼ -32.3%on this news
8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI ANNOUNCES PRICING OF $5 MILLION PUBLI
CEL-SCI Corporation has announced a $5 million public offering of 16,130,000 shares of common stock, priced at $0.31 per share. The gross proceeds will be directed towards the further development of Multikine, an investigational cancer immunotherapy, and general corporate purposes. The offering is set to close on December 31, 2024, pending the satisfaction of customary closing conditions. CEL-SCI's Multikine has received Orphan Drug designation and is preparing for a confirmatory study involving 212 patients with specific cancer characteristics.
Read more →CVM▲ +5.2%on this news
CEL-SCI's Multikine Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and
CEL-SCI Corporation reported that its Multikine treatment has increased the 5-year survival rate for locally advanced resectable head and neck cancer patients to 82.6%. This data, presented at ESMO 2024, shows significant survival benefits, particularly for patients deemed at low risk for recurrence who received only radiotherapy after surgery. The FDA has approved a confirmatory Registration Study, which will focus on a well-defined patient population to optimize treatment outcomes further. These findings highlight the potential of Multikine as a key immunotherapy option in this patient demographic.
Read more →CVM▲ +8.3%on this news
NEWS 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI'S PHASE 3 POPULATION ANALYSIS FOR UPCOMING CO
CEL-SCI Corporation announced positive results from a bias analysis of its Phase 3 study for Multikine in head and neck cancer, showing well-balanced patient demographics. The analysis concluded that there was no bias affecting the results, reinforcing confidence in the treatment’s efficacy. The upcoming confirmatory registration study, approved by the FDA, aims to enroll 212 patients to further validate Multikine's promising survival rates versus control. Notably, the treatment demonstrated a 73% five-year survival rate compared to 45% for the control group.
Read more →CVM▲ +8.3%on this news
Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI ANNOUNCES PRICING OF $10.8 MILLION OFFERING Vienna, Vir
CEL-SCI Corporation has announced a pricing deal for a best-efforts offering of 10,845,000 shares of its common stock at $1.00 per share, totaling gross proceeds of approximately $10.8 million. The funds raised will be directed towards the development of Multikine, an investigational therapy for cancer, and for general corporate purposes. The offering is scheduled to close on July 29, 2024, subject to customary conditions. CEL-SCI has previously completed a pivotal Phase 3 trial for Multikine and plans to start a confirmatory trial in Q4 2024.
Read more →CVM▼ -11.2%on this news
Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI PRESENTS HEAD & NECK CANCER DATA AT IDDST ANNUAL CONGRE
CEL-SCI Corporation presented new data at the IDDST Annual Congress demonstrating Multikine's effectiveness in treating head and neck cancer. The treatment showed a 73% survival rate at five years compared to 45% for the control group. Multikine significantly reduced the risk of death by half, leading the company to pursue a confirmatory registration study with the FDA. The immunotherapy targets patients with low tumor cell PD-L1 expression, offering a novel approach compared to existing checkpoint inhibitors.
Read more →CVM▼ -13.7%on this news
Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI ANNOUNCES PRICING OF $7.75 MILLION PUBLIC OFFERING OF C
CEL-SCI Corporation announced a public offering of 3,875,000 shares of common stock priced at $2.00 per share to raise approximately $7.75 million. The offering is expected to close on February 13, 2024, and the proceeds will be used to advance the development of Multikine, a cancer immunotherapy. CEL-SCI's approach aims to enhance immunity before standard therapies, showing promising survival data in its Phase 3 clinical trial for head and neck cancer patients. The company plans to submit a study protocol to the FDA in early 2024 for potential confirmed trials and accelerated approval pathways.
Read more →CVM▼ -22.6%on this news
Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI ANNOUNCES PRICING OF $5 MILLION OFFERING OF COMMON STOC
CEL-SCI Corporation announced a pricing of a $5 million offering of 2,490,000 shares of its common stock at $2.00 per share. The offering, set to close on November 20, 2023, will help fund the continued development of its lead investigational therapy, Multikine, as well as general corporate purposes. CEL-SCI has received Orphan Drug Status from the FDA for Multikine, reflecting its potential in treating head and neck cancer. The offering is managed by ThinkEquity and adheres to the requirements set by the U.S. Securities and Exchange Commission.
Read more →CVM▲ +8.3%on this news· ran to +53% by day 3
8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com NYSE American: CVM COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI Issues Letter to S
CEL-SCI Corporation has issued a letter to shareholders detailing progress on its cancer treatment, Multikine. The CEO, Geert Kersten, highlighted the success of Multikine in improving survival rates for head and neck cancer patients, asserting that the company will seek immediate regulatory approval. Recent data indicates significant pre-surgical benefits to patients receiving the treatment. With a capable manufacturing unit in place, CEL-SCI aims to expedite access to Multikine for patients in need.
Read more →CVM▲ +41.1%on this news
8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com NYSE American: CVM COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 5-Year Head & Neck Cancer
CEL-SCI Corporation announced at the ESMO 2023 conference that its immunotherapy drug Multikine significantly increased 5-year survival rates for head and neck cancer patients, from 45% to 73%. The company finalized its target population criteria for regulatory submissions, focusing on patients with low PD-L1 expression. The compelling results from the Phase 3 trial support immediate regulatory approval requests in multiple regions, including the UK, Europe, and the US. Additionally, physicians can now identify eligible patients quickly through routine cancer screenings, enhancing Multikine's potential accessibility.
Read more →CVM▼ -8.8%on this news
Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI ANNOUNCES CLOSING OF PUBLIC OFFERING Vienna, VA
CEL-SCI Corporation announced the completion of a public offering of 2,500,000 shares at $2.00 each, generating $5 million in gross proceeds. The funds from this offering will be directed towards the ongoing development of Multikine, a promising cancer immunotherapy, as well as for general corporate purposes. This offering was facilitated under an effective shelf registration statement filed with the SEC. CEL-SCI is focused on activating the immune system to combat cancer and infectious diseases, with Multikine currently undergoing further evaluation following its Phase 3 trials.
Read more →CVM▲ +11.7%on this news· ran to -23% by day 3shared move
8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI ANNOUNCES PRICING OF PUBLIC OFFERING
CEL-SCI Corporation announced the pricing of an underwritten public offering of 2,500,000 shares at $2.00 per share, aiming for gross proceeds of $5 million. The offering is set to close on July 20, 2023, pending customary closing conditions. Proceeds will fund the development of Multikine, the company's investigational cancer therapy, which has received FDA's Orphan Drug Status.
Read more →CVM▲ +9.4%on this news· ran to +22% by day 1shared move
8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI CONCLUDES POSITIVE MEETING WITH U.S.
CEL-SCI Corporation held a productive meeting with the U.S. FDA regarding its Multikine treatment for head and neck cancer. The FDA recognized the need for improved therapies and provided favorable feedback on CEL-SCI's development plans. The company is also seeking approvals in Europe and Canada, where commercialization could potentially begin in 2024. CEL-SCI remains focused on generating confirmatory data required for further regulatory processes.
Read more →CVMBoone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI REPORTS PHASE 3 TUMOR PD-L1 BIOMARKER DATA DEMONSTRATE
CEL-SCI Corporation has presented promising results from a Phase 3 study showing that Multikine significantly increases overall survival in patients with low PD-L1 levels in head and neck cancer. The company suggests that a combination therapy with existing checkpoint inhibitors could further improve patient outcomes. The new data was disclosed at the American Head and Neck Cancer Society's conference, highlighting Multikine's potential clinical benefits compared to traditional therapies. CEL-SCI is seeking marketing approval for Multikine in the USA, Canada, the UK, and the EU.
Read more →CVMBoone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI ANNOUNCES $1.35 MILLION UNDERWRITTEN CONFIDENTIALLY MAR
CEL-SCI Corporation announced a $1.35 million underwritten confidential public offering of 794,117 shares of common stock at $1.70 per share. The offering aims to fund the continued development of its cancer immunotherapy product, Multikine. The transaction is scheduled to close on May 2, 2023, and includes a 30-day over-allotment option for the underwriter. CEL-SCI is a Phase 3 cancer immunotherapy company based in Vienna, Virginia, and has received Orphan Drug Designation from the FDA for Multikine.
Read more →CVM▲ +15%on this news
8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI TO PURSUE CANADA'S CONDITIONAL APPROV
CEL-SCI Corporation is seeking conditional approval from Health Canada for its investigational immunotherapy, Multikine, for treating head and neck cancer. Following a productive pre-submission meeting, the company plans to leverage a Notice of Compliance with Conditions to expedite access for patients. Multikine has demonstrated promising clinical outcomes in a Phase 3 trial, including significant overall survival improvements compared to traditional treatment methods. The company is also working on its Biologics License Application for the U.S. FDA and exploring marketing approval in other countries.
Read more →CVM▼ -5.2%on this news· ran to -16% by day 3
Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI's Multikine Phase 3 Cancer Study Shows 43% Survival Ext
CEL-SCI Corporation announced promising results from its Phase 3 study of Multikine, demonstrating a 43% survival extension for patients with locally advanced squamous cell carcinoma of the head and neck. The study, presented at the ECHNO Congress, highlighted superior outcomes for patients receiving Multikine alongside standard treatment compared to those receiving standard treatment alone. CEL-SCI plans to submit a Biologics License Application for Multikine to the FDA, focusing on a patient population with limited treatment options. The data suggests a significant improvement in survival rates and progression-free survival for those treated with Multikine, signaling potential for future regulatory approval.
Read more →CVM8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI'S PHASE 3 DATA PRESENTED AT ESMO 2022
8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI'S PHASE 3 DATA PRESENTED AT ESMO 2022: NEOADJUVANT MULTIKINE ACHIEVED GROUNDBREAKING TUMOR RESPONSE & EXT
Read more →CVM8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com CEL-SCI CORPORATION ANNOUNCES PHASE 3 MULTIKINE HEAD AND NECK CANCER RESULTS POSTED ON CLINICALTRIALS.GOV The "P
8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 CEL-SCI CORPORATION ANNOUNCES PHASE 3 MULTIKINE HEAD AND NECK CANCER RESULTS POSTED ON CLINICALTRIALS.GOV The "Proposed Indication" for Multikine that will be submitted to the FDA in a license appl
Read more →CVM8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI CORPORATION ISSUES LETTER TO SHAREHOL
cvm_ex99.htm EXHIBIT 99 NEWS RELEASE 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI CORPORATION ISSUES LETTER TO SHAREHOLDERS Vienna, VA, July 7, 2021 --
Read more →CVMN EWS RELEASE 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI ANNOUNCES BOUGHT DEAL OFFERING Vienn
8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI ANNOUNCES BOUGHT DEAL OFFERING Vienna, VA, June 8, 2021 -- CEL-SCI Corporation (NYSE American: CVM), a P
Read more →CVMN EWS RELEASE 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI ANNOUNCES BOUGHT DEAL OFFERING Vienn
N EWS RELEASE 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI ANNOUNCES BOUGHT DEAL OFFERING Vienna, VA, December 8, 2020 -- CEL-SCI Corporation (NYSE Ame
Read more →CVMBoone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI ANNOUNCES BOUGHT DEAL OFFERING Vienna, VA
8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI ANNOUNCES BOUGHT DEAL OFFERING Vienna, VA, March 23, 2020 -- CEL-SCI Corporation (NYSE American: CVM), a Ph
Read more →CVMN EWS RELEASE 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI REPORTS RECENT DATA REVIEW BY THE IN
8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI REPORTS RECENT DATA REVIEW BY THE INDEPENDENT DATA MONITORING COMMITTEE FOR ITS PIVOTAL PHASE 3 HEAD AND NEC
Read more →CVMCEL-SCI CORPORATION RELEASES LETTER TO SHAREHOLDERS Vienna, VA
CEL-SCI CORPORATION RELEASES LETTER TO SHAREHOLDERS Vienna, VA, May 8, 2019 -- The following letter was sent by CEL-SCI Corporation (NYSE American: CVM) to its CEL-SCI Shareholders: first 4 months of this year have already been very positive for us. Our Phase 3 head and neck
Read more →CVMN EWS RELEASE 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI RECEIVES ABOUT $8 MILLION FROM WARRA
CEL-SCI RECEIVES ABOUT $8 MILLION FROM WARRANT Vienna, VA, October 23, 2018 - CEL-SCI Corporation (NYSE American: CVM) announced today it has received just under $8 million through the exercise of warrants to purchase shares of the Company's common stock during the past 3 mo
Read more →CVMN EWS RELEASE 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI ANNOUNCES THAT THE NYSE AMERICAN APP
CEL-SCI ANNOUNCES THAT THE NYSE AMERICAN APPROVES PLAN Vienna, VA, August 17, 2018 - CEL-SCI Corporation (NYSE American: CVM) announces that the NYSE American (the Exchange ) has accepted the Company's plan to bring itself into compliance with the Exchange's continued listin
Read more →CVMN EWS RELEASE 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI ANNOUNCES $5 MILLION REGISTERED DIRE
CEL-SCI ANNOUNCES $5 MILLION REGISTERED DIRECT Vienna, VA, June 28, 2018 -- CEL-SCI Corporation (NYSE American: CVM) today announced it has entered into definitive agreements with institutional investors for an offering of shares of common stock with gross proceeds of approx
Read more →CVMGavin de Windt Investor Relations Manager Phone: 703 506-9460 Email address: gdewindt@cel-sci.com CEL-SCI Receives $2.1 Million from Warrant Exercises Vienna, VA
CEL-SCI Receives $2.1 Million from Warrant Exercises Vienna, VA, June 27, 2018 - CEL-SCI Corporation (NYSE American: CVM), in response to shareholder questions, updates its shareholders on the amount of money received from warrant exercises since April 1, 2018. Since that t
Read more →CVMN EWS RELEASE 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI ANNOUNCES ADJUSTMENT TO WARRANT EXER
CEL-SCI ANNOUNCES ADJUSTMENT TO WARRANT EXERCISE PRICE Vienna, VA, April 3, 2018 CEL-SCI Corporation (NYSE American: CVM) announced today that the outstanding Series S warrants (CUSIP number 150837177) that are publicly traded under the symbol CVM WS on the NYSE American hav
Read more →CVMBoone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. placecountry-regionUSA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI REPORTS RECENT DATA REVIEW BY THE IN
form8k801ex991dec-17.txt 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. placecountry-regionUSA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI REPORTS RECENT DATA REVIEW BY THE INDEPENDENT DATA MONITORING
Read more →CVMGavin de Windt Investor Relations Manager Phone: 703 506-9460 Email address: gdewindt@cel-sci.com CEL-SCI Announces $3.5 Milli on Registered Direct Offering Vienna, VA
CEL-SCI Announces $3.5 Million Registered Direct Offering Vienna, VA, August 23, 2017 - CEL-SCI American: CVM) today announced it has entered into a definitive agreement with institutional investors for an offering of shares of common stock with gross proceeds of approximate
Read more →CVMBoone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 U.S. FDA REMOVES CLINICAL HOLD ON CEL-SCI'S PHASE 3 HEAD & NECK
form8kitem801ex99aug-17.txt 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 U.S. FDA REMOVES CLINICAL HOLD ON CEL-SCI'S PHASE 3 HEAD & NECK CANCER TRIAL The St
Read more →CVMN EWS RELEASE 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI SUBMITS FDA RESPONSE FOR ITS PHASE 3
N EWS RELEASE 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI SUBMITS FDA RESPONSE FOR ITS PHASE 3 HEAD AND 928 patients have been enrolled, treated, and a
Read more →CVMBoone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI ANNOUNCES CHANGE TO THE DATE OF ITS ANNUAL MEETING Vien
form8kitem801ex99may-17.txt 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI ANNOUNCES CHANGE TO THE DATE OF ITS ANNUAL MEETING Vienna, VA, Friday, May 1
Read more →CVMCEL-SCI Corporation 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI ANNOUNCES $1.51 MILLION REGIST
form8kitem101ex99may-17.txt 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI ANNOUNCES $1.51 MILLION REGISTERED DIRECT OFFERING Vienna, VA, Friday, May 1
Read more →CVMN EWS RELEASE 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI ANNOUNCES $1.5 MILLION REGISTERED DI
N EWS RELEASE 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI ANNOUNCES $1.5 MILLION REGISTERED DIRECT Vienna, VA, Friday, March 9, 2017 - CEL-SCI Corporat
Read more →CVMCEL-SCI CORPORATION 8229 Boone Boulevard Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI GIVES UPDATE ON PARTIAL CLINICA
form8kitem801ex99march-17.txt 8229 Boone Boulevard Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI GIVES UPDATE ON PARTIAL CLINICAL HOLD ON PHASE 3 HEAD AND NECK CANCER STUD
Read more →CVMBoone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI Announces That the NYSE MKT Approves Plan VIENNA, VA
form8kitem301ex99feb-17.txt 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI Announces That the NYSE MKT Approves Plan VIENNA, VA, February 27, 2017 - C
Read more →CVM8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI ANNOUNCES $1.0 MILLION REGISTERED DIR
8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI ANNOUNCES $1.0 MILLION REGISTERED DIRECT Vienna, VA, Friday, February 17, 2017 - CEL-SCI Corporation (NYSE
Read more →CVMGavin de Windt Investor Relations Manager Phone: 703 506-9460 Email address: gdewindt@cel-sci.com CEL-SCI Announces Proposed Public Offering of Common Stock and Warrants VIENNA, VA
VIENNA, VA, December 1, 2016 - CEL-SCI Corporation (NYSE MKT: and other conditions shares of its common stock and warrants to purchase common stock. The securities are to be sold by CEL-SCI subject to market and other conditions in a public CEL-SCI currently intends to use t
Read more →CVMCEL-SCI CORPORATION Contact: Gavin de Windt Investor Relations Manager Phone: 703 506-9460 Email address:gdewindt@cel-sci.com CEL-SCI
form8k801exh999-16.txt EXH 00 - PR RE STUDY HOLD Contact: Gavin de Windt Investor Relations Manager Email address:gdewindt@cel-sci.com CEL-SCI REPORTS CLINICAL HOLD ON HEAD AND NECK CANCER STUDY VIENNA, VA, September 26, 2016 - CEL-SCI Corporation (NYSE MKT: CVM) announced
Read more →CVMN EWS RELEASE 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI ANNOUNCES $5 MILLION REGISTERED DIRE
N EWS RELEASE 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI ANNOUNCES $5 MILLION REGISTERED DIRECT OFFERING Vienna, VA, August 23, 2016 - CEL-SCI Corpora
Read more →CVMGavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI Announces $5 Million Registered Direct Offering Vienna, VA
CEL-SCI Announces $5 Million Registered Direct Offering Vienna, VA, May 18, 2016 - CEL-SCI Corporation (NYSE MKT: CVM) today announced it has entered into a definitive agreement with a single healthcare dedicated institutional investor to purchase approximately 10 million shares
Read more →CVMGavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI Announces Proposed Public Offering of Common Stock and Warrants Vienna, VA
form8kdawsonex991oct-15.txt EXH. 99.1 - PRESS RELEASE 10-22-15 CEL-SCI Announces Proposed Public Offering of Common Stock and Warrants Vienna, VA, October 22, 2015 - CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company") today announced that it has commenced an offe
Read more →CVMBoone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND
form8kitem101ex991may-15.txt 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND WARRANTS Vienna, VA
Read more →CVMN EWS RELEASE 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone: (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI RECEIVES AUTHORIZATION TO CONDUCT I
N EWS RELEASE 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone: (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI RECEIVES AUTHORIZATION TO CONDUCT ITS PHASE 3 MULTIKINE TRIAL IN ITALY Italy is 23rd country
Read more →CVMBoone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone: (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI RECEIVES AUTHORIZATION TO CONDUCT ITS PHASE 3 MULTIKIN
8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone: (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI RECEIVES AUTHORIZATION TO CONDUCT ITS PHASE 3 MULTIKINE TRIAL IN SPAIN Spain is 22nd country to authorize C
Read more →CVMCEL-SCI Corp.'s CEO Geert Kersten Interviewed by The Life Sciences Report
SAN FRANCISCO, CA--(Marketwired - Feb 23, 2015) - Control and manipulation of the immune system is the underlying basis behind vaccinations in the fight against dangerous infectious diseases, but using immunotherapies to treat cancers and autoimmune disorders has been limited. Th
Read more →CVMBoone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI CORPORATION TO RAISE $1 MILLION IN REGISTERED DIRECT OF
form8kitem101offerex99oct-14.txt 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI CORPORATION TO RAISE $1 MILLION IN REGISTERED DIRECT OFFERING Vienna, V
Read more →CVMN EWS RELEASE 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI CORPORATION ANNOUNCES PROPOSED PUBLI
N EWS RELEASE 8229 Boone Boulevard, Suite 802 Vienna, VA 22182. USA Telephone (703) 506-9460 www.cel-sci.com COMPANY CONTACT: Gavin de Windt CEL-SCI Corporation (703) 506-9460 CEL-SCI CORPORATION ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND WARRANTS Vienna, VA, Octob
Read more →CVMCEL-SCI Has Been Cleared to Begin Patient Enrollment
LOS ANGELES, July 23, 2014 (GLOBE NEWSWIRE) -- Yesterday morning, CEL-SCI Corporation (NYSE MKT:CVM) announced that Turkey's Ministry of Health had cleared the company to begin patient enrollment in CEL-SCI's global pivotal Phase III Head and Neck Cancer clinical trial of its inv
Read more →CVMCEL-SCI CORPORATION NEWS 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI Corporation Announces Pro
form8klaidlawexh9914-14.txt EXH. 99.1 - PRESS RELEASE 4/11/14 RE PROP. PUB. OFFERING CEL-SCI CORPORATION NEWS 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 C
Read more →CVMCEL-SCI CEO Geert Kersten to Be Interviewed Live Today on Clear Channel Business Talk Radio
VIENNA, VA--(Marketwired - Mar 25, 2014) - CEL-SCI Corporation (NYSE MKT: CVM), a leading research and development company dedicated to improving the treatment of cancer and other diseases by utilizing the immune system, today announced that CEO Geert Kersten will be interviewed
Read more →CVMCEL-SCI CORPORATION NEWS RELEASE 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI ANNOUNCES INITIAT
form8karbexh99nov-13.txt CEL-SCI CORPORATION NEWS RELEASE 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI ANNOUNCES INITIATION OF ARBITRATION AGAINST F
Read more →CVMBoone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI CORPORATION ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMO
form8kitem101exh991oct-13.txt EXH. 99.1 PRESS RELEASE 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI CORPORATION ANNOUNCES PROPOSED PUBLIC OFFERING OF
Read more →CVMCEL-SCI CORPORATION 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI ANNOUNCES THAT NYSE MKT APPROV
form8kitem801ex99aug-13.txt EXH. 99 PRESS RELEASE RE COMPLIANCE 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI ANNOUNCES THAT NYSE MKT APPROVES PLAN V
Read more →CVMBoone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI REPORTS ON NYSE MKT NONCOMPLIANCE NOTICE AND COMPLIANCE
form8kitem301exh99july-13.txt 8229 Boone Boulevard, Suite 802 COMPANY CONTACT: Vienna, VA 22182. USA Gavin de Windt Telephone (703) 506-9460 CEL-SCI Corporation www.cel-sci.com (703) 506-9460 CEL-SCI REPORTS ON NYSE MKT NONCOMPLIANCE NOTICE AND COMPLIANCE PLAN Vienna, VA, J
Read more →Competitive Position
How CVM ranks across every disease it competes inCompetitive Position is a premium feature
See how CVM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial